Image: Associated Press

Af­ter a late-stage miss, No­var­tis touts an­oth­er En­tresto analy­sis to con­vince the FDA to ex­pand the block­buster's la­bel

Fresh af­ter get­ting its keen­ly watched sick­le cell treat­ment en­dorsed by the FDA, No­var­tis is pulling out all the stops to ex­pand the use of heart ther­a­py En­tresto us­ing a raft of analy­ses af­ter the drug “nar­row­ly” failed a cru­cial late-stage test.

En­tresto is a top sell­er for No­var­tis and is cur­rent­ly ap­proved for HFrEF (for­mer­ly known as sys­tolic heart fail­ure) — in these pa­tients the heart mus­cle does not con­tract ef­fec­tive­ly, re­duc­ing the lev­el of oxy­gen-rich blood pumped in­to to the body. The drug is ad­min­is­tered twice dai­ly and is de­signed to cut the strain on the fail­ing heart.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.